Kornimate/medical-research-clean huggingface dataset:
physical activity in persons newly diagnosed with multiple sclerosis

Conditions: Multiple Sclerosis (MS)

Summary: this single group pre-post pilot intervention will examine the feasibility and initial effect of a 12-week behavioral intervention, based on the behavior change wheel and capability-opportunity-motivation-behavior (com-b) model and remotely delivered through electronic newsletters and online one-on-one video conferencing, for promoting physical activity and secondarily reducing fatigue and quality of life in persons newly diagnosed with ms (diagnosed with ms within the past 2 years). the investigators hypothesize the proposed 12-week intervention will be feasible based on process, resource, management, and scientific outcomes. the investigators further hypothesize that individuals who receive the 12-week intervention will demonstrate an increase in physical activity behavior, particularly daily step counts, and reduce fatigue.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old * diagnosed with multiple sclerosis for 2 or fewer years * fully ambulatory * no relapse within the last 30 days * non-active (godin leisure-time exercise questionnaire - health contribution score \< 14) * able to read 14-point font size * internet \& video conferencing access * undergoing disease-modifying therapy exclusion criteria: * pregnancy * moderate or high risk for undertaking physical activity (≥ 2 affirmatives on the physical activity readiness questionnaire)

Keywords: physical activity newly diagnosed with ms behavior change multiple sclerosis
the accuracy and safety of coronary artery contrast-enhanced magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle

Conditions: Coronary Heart Disease

Summary: this is a single-center, prospective, controlled and diagnostic clinical trial which will enroll 30 patients scheduled for coronary angiography in china.patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.in order to evaluate the safety of polysaccharide superparamagnetic iron oxide nanoparticle, patients will detect iron levels in peripheral and tissue before and after the examination.the main indicators of the study are the degree of coronary artery stenosis and the stability of coronary atherosclerotic plaque assessed by contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle.


Eligibility criteria:
inclusion criteria: * age ≧ 18 years, \< 75 years; * patients who planned coronary angiography ; * patients with normal renal function or ckd stage 1-3; * patients themselves or authorized families to sign informed consent voluntarily. exclusion criteria: * patients who were allergic to iodine contrast agent or had allergic history or allergic constitution to iron and dextran; * patients who can ' t accept magnetic resonance examination because of psychological ( such as autism syndrome ) or physical reasons ( such as metal retention in the body ); * malignancies or other comorbid conditions with life expectancy less than 1 year; * pregnant or lactating woman; * hearing impaired persons; * cardiac function grade iii-iv; * history of coronary stenting or coronary artery bypass grafting; * patients who were taking other iron agents orally or intravenously; * patients with hemosiderin deposition or hemochromatosis; * patients with acute coronary syndromes; * any other patients that researcher deems it's unsuitable to be admitted.

Keywords: ultrasmall superparamagnetic particles of iron oxide contrast-enhanced magnetic resonance plaque stability
bivalirudin in acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: the purpose of the study is to evaluate the efficacy and safety of bivalirudin in ami patients with des. this is a prospective, randomized, single-blind, active drug controlled multicenter clinical research and the study would enrolled a total of 380 ami patients undergoing percutaneous coronary intervention (pci) to one of two antithrombotic regimens: bivalirudin alone, or unfractionated heparin alone. all enrolled patients would be followed-up to 30 days.

this is a prospective, randomized, single-blind, active drug controlled multicenter clinical research and the study would enrolled a total of 380 ami patients undergoing percutaneous coronary intervention (pci) to one of two antithrombotic regimens: bivalirudin alone, or unfractionated heparin alone. all enrolled patients would be followed-up to 30 days. the purpose of the study is to evaluate the efficacy and safety of bivalirudin in ami patients with des.

Eligibility criteria:
inclusion criteria: 1. age 18 to 80 years old 2. planned emergency pci for acute myocardial infarction (stemi) symptom onset within 12h for stemi (or within 12-24 hrs for patients have unrelieved chest pain, continuous st elevation or new developed lbbb) 3. provide written informed consent. exclusion criteria: 1. age \ 80 years. 2. any anticoagulant drugs were regularly used within 3 months. 3. any anticoagulant agents were used 48 h before randomization. 4. active bleeding or bleeding constitution, bleeding tendency, including the recent retina or vitreous hemorrhage (1 months), gi or urinary tract hemorrhage (3 months), cerebral hemorrhage (6 months) or cerebral infarction history (3 months), etc. 5. hemoglobin \< 90 g/l or platelet count \< 100 \* 109 / l. 6. untreated or uncontrolled hypertension \> 180/110 mmhg. 7. elevated alt level higher than three times of the normal upper limit;severe renal insufficiency (egfr \< 30 ml/min / 1.73 m2). 8. heparin induced thrombocytopenia. 9. suspicious aortic dissection, pericarditis and subacute bacterial endocarditis. 10. known allergy to the study drugs and instruments (ufh, bivalirudin, aspirin and clopidogrel, stainless steel, contrast agents, etc.), or those allergic constitution. 11. pregnancy , lactation or plan to be pregnant. 12. known serious progressive diseases such as malignant tumor or prognosis of the patients with severe failure;the survival time \< 6 months. 13. unsuitable for pci. 14. attended any clinical trial 1 month before randomised.

Keywords: bivalirudin acute myocardial infarction percutaneous transluminal coronary angioplasty
the effects of prolonged standing compared to prolonged sitting on postprandial lipemia

Conditions: Metabolic Syndrome; Atherosclerosis

Summary: the effects of 12 hours of prolonged standing will be compared to prolonged standing on a high fat tolerance test the following day. plasma triglycerides, insulin, and glucose will be measured in a crossover study design.


Eligibility criteria:
inclusion criteria: - exclusion criteria: * heart problems * coronary artery disease * hypertension * respiratory problems * musculoskeletal problems that prevent prolonged standing or sitting * obesity * susceptibility to fainting
18f-fdg pet/mr imaging for differentiation of serous from non-serous pancreatic cystic neoplasms: a pilot study

Conditions: Pancreatic Cystic Neoplasms

Summary: the overlap of morphological imaging features results in many incidentally detected pancreatic cystic neoplasms going undiagnosed, including benign serous cystic neoplasms (scn) and potentially malignant mucinous lesions (nonserous). the diagnostic ambiguity then lead to invasive procedures such as endoscopic ultrasonography (eus), unwarranted surgical resection on scn lesions or the need for long term periodic surveillance with delayed diagnosis of potentially malignant nonserous lesions. therefore, precise differentiation of scn from nonserous cystic neoplasms is highly desirable. the 18f-fluorodeoxyglucose (fdg) accumulation in tumor cells, which is induced by high expression of glucose transporter proteins (mainly include glut-1 and -3), can be used to discriminate malignant and benign pancreatic cystic tumors in positron emission tomography (pet) imaging. glut-1 expression has also been documented in benign scn while no such evidence exists in potentially malignant nonserous cystic neoplasms. based on this evidence, investigators will conduct a pilot study to evaluate if integrated 18f-fdg pet/mr imaging with simultaneous mr and pet acquisition is helpful in differentiation of scn from nonserous lesions.


Eligibility criteria:
inclusion criteria: -patients with known pancreatic cystic lesions, including suspected pancreatic serous cystic neoplasms and non-serous cystic neoplasms exclusion criteria: * general contraindications to mri such as pacemaker, brain aneurysm clip etc. - * pregnancy * age below 18 years * estimated gfr (egfr \< 30 ml/min) * mri contrast allergy;
response evolution chart

Conditions: Obesity; Overweight; Motivation; Adherence, Patient

Summary: this study evaluates patient response to a motivation evolution chart for a medical-nutrition intervention as a continuation of a previous study: adherence to an overweight and obesity treatment available at: https://www.ncbi.nlm.nih.gov/pubmed/25101227


Eligibility criteria:
inclusion criteria: * voluntary assistance * clinical diagnosis of overweight * clinical diagnosis of obesity * patient desire to improve their aesthetic image and health status exclusion criteria: * this study does not consider patients who tried a diet to lose weight in the previous month or earlier

Keywords: motivation treatment adherence waist circumference obesity overweight
effectiveness of folic acid supplementation in acute watery diarrhea among children under 5 years of age

Conditions: Diarrhoea;Acute

Summary: folic acid is a palatable and easily available drug with no serious adverse effects. l-methylfolate is its biologically activated form and is preferred because of its direct availability for certain metabolic processes. as there is no specific and safe drug available that may help in decreasing the duration of diarrhea, purging rate or consistency of stools; and having known the theoretical benefits of folic acid in this regard, it would be appropriate to assess the effectiveness of l-methylfolate among children with diarrhea.

after approval from the institutional review board of king edward medical university, mayo hospital, lahore, all children diagnosed with acute watery diarrhea as per operational definition fulfilling the inclusion criteria, presenting to the department of pediatrics, mayo hospital, will be enrolled in this study. informed written consent will be taken from the parents/guardians of all participants. a detailed history and examination of each subject would be done by an investigator at presentation. patients will be randomized in two groups - a and b by lottery method. there will be 162 patients in each group. the treatment regimen that includes breast feeding, nutritional advice, rehydration plan; ort by low osmolar ors or intravenous rehydration (if required) and zinc sulphate will be given according to the who guidelines to all patients of both groups. children under 1 year of age in group a will receive 3 drops (90mcg) of l-methylfolate calcium) while those older than 1 year of age will be given 5 drops (150mcg). subjects in group b will receive equal amount of distilled water as placebo (i.e. 3 drops to \ 1 yr. frequency and grades of loose stools in both groups will be assessed daily and written down on a predesigned proforma.

Eligibility criteria:
inclusion criteria: * children aged 2months- 5 years * both genders * acute watery diarrhea as per operational definition * diarrhea of less than 7-day duration exclusion criteria: * severely malnourished children \<3 sd * bloody diarrhea * prolonged (7-14 days duration), persistent (\>14 days duration) or chronic diarrhea (\>4weeks duration) * those who received folic acid within the last 14 days * hospital-acquired diarrhea (diarrhea occurring after 48hrs of stay in hospital) * antibiotic-associated diarrhea. * presence of other co morbid conditions like pneumonia, sepsis, meningitis, etc.

Keywords: acute watery diarrhea folic acid l-methylfolate
efficacy and safety of xg-102 in reduction of post-cataract surgery intraocular inflammation and pain

Conditions: Inflammation; Pain; Cataract

Summary: the purpose of this study is to evaluate the clinical efficacy and safety of xg-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.


Eligibility criteria:
inclusion criteria: * have provided written informed consent, approved by the appropriate institutional review board; * be greater than or equal to 18 years of age of either sex or any race; * be planning to undergo unilateral cataract extraction via phacoemulsification and posterior chamber intraocular lens (pciol) implantation in the study eye; * have a pin-hole visual acuity (va) \< 1.0 logarithm of the minimum angle of resolution (logmar) in the operative eye and fellow eye as measured using an early treatment for diabetic retinopathy study (etdrs) chart at visit 1; * (for females of childbearing potential) agree to have urine pregnancy testing performed at visit 1 (must be negative) and at exit visit; must not be lactating; and must agree to use a medically acceptable form of birth control1 throughout the study duration. women of childbearing potential include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). exclusion criteria: * have a known sensitivity or allergy to the class of medication of the active ingredient in the study medication or any of the study medication's components; * have any intraocular inflammation (e.g., white blood cells or flare) present in the study eye at the visit 1slit lamp examination; * have a score greater than "0" on the ocular pain assessment at visit 1 or 2 in the study eye; * have an immunosuppressive or an autoimmune disease that in the opinion of the investigator could affect intraocular inflammation or the normal healing process of the eye; * have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing; * currently have suspected or known malignancy or be currently receiving antineoplastic therapy; * be a female who is currently pregnant, planning a pregnancy, lactating, not using a medically acceptable form of birth control throughout the study duration, or have a positive urine pregnancy test at visit 1; * use anti-inflammatory agents, analgesics/pain relievers (including opioids, narcotics and other pain medications) or immunomodulating agents, systemically, or in either eye, and/or use medications for benign prostatic hyperplasia (bph), from the washout period through the duration of the study
prehabilitation for patients undergoing lung cancer surgery

Conditions: Lung Cancer (NSCLC)

Summary: major surgery has been linked to running a marathon as in both represent large endeavours where the body will experience an increase in demands to supply the necessary energy. it has been alledged that, as one would train to prepare for a marathon, the same should be applied to surgery. the process of getting ready and/or fitter for surgery is frequently referred to as prehabilitation and it usually involves interventions on improving nutrition and diet, getting fit and improve emotional wellness. prehabilitation can improve the recovery after surgery and reduce the time spent in hospital afterwards. this research seeks to determine whether a home based program of increased physical activity and breathing training can improve patients' physical and respiratory function in preparation for lung cancer surgery.

patients with lung cancer who are scheduled to undergo lung resection surgery will be provided with a digitally-enabled, remotely-monitored prehablitation program. the intervention will consist of the following components: i) general education; ii) inspiratory muscle training; iii) physical activity coaching; and iv) home-based exercise training. the program will be supported with a mobile app and weekly telehealth sessions with one experienced physiotherapist. participants will be assessed at baseline and at the end of the intervention, prior to surgery. participants will be contacted and scheduled to undergo face-to-face assessments on lung function, respiratory muscle strength, and functional capacity both at baseline and after the prehabilitation program.

Eligibility criteria:
inclusion criteria: * diagnosis of lung cancer and scheduled for lung resection surgery * ability to understand and speak english to follow instructions and complete the intended assessments. * age ≥ 18 years at the point of baseline screening * provide written informed consent for the trial * sufficient digital literacy to use a smartphone and mobile app * no contraindications for exercise exclusion criteria: * other cancer diagnoses than lung cancer * surgery scheduled in less than one week * unstable psychiatric, cognitive or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Keywords: prehabilitation inspiratory muscle training exercise therapy lung cancer telehealth
diagnosing frontotemporal lobar degeneration

Conditions: Corticobasal Syndrome; Progressive Supranuclear Palsy; Behavioral Variant Frontotemporal Dementia; Semantic Dementia; Progressive Nonfluent Aphasia; Amyotrophic Lateral Sclerosis And/or Frontotemporal Dementia

Summary: to establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical ftld syndromes

the goal of this study is to determine the best diagnostic test for diagnosing frontotemporal lobar degeneration. to accomplish this, the current study will evaluate different tests: brain imaging, skin biopsy, body fluid samples (blood and cerebrospinal fluid), thinking abilities, everyday functioning, and brain autopsy. the study team hopes that this information can be used to guide diagnosis and further understanding of mechanism of disease in frontotemporal lobar degeneration and possibly treatment in the future.

Eligibility criteria:
inclusion criteria: * participant must have a reliable study partner who can provide an independent evaluation of functioning. * able to read, understand and speak english for neuropsychological testing. * all subjects must meet one of these diagnostic criteria (a) probable behavioral variant ftd, (b) mri-supported non-fluent variant ppa; (c) mri-supported semantic variant ppa and \[18f\]t807 negative (d) probable cbs: using current criteria for cbs(27); (e) psp: inclusion criteria for psp are based upon the national institute of neurological disorders and stroke society of progressive supranuclear palsy (ninds-spsp) (f) ftd-mnd * control subjects must have a normal neurological exam, a cdr sum of boxes = 0, and mmse score equal to or greater than 28 exclusion criteria: * patients with clinical, imaging or csf a beta/ tau profile consistent with ad * history of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded. * premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from pet study. * presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
following outcomes remotely within addiction recovery domains

Conditions: Opioid Use Disorder

Summary: the aim of this study is to describe outcome of people with opioid use disorder over the long-term by collecting monthly and yearly data on their recovery. adults with opioid use disorder who participate will complete surveys monthly online and once per year by phone about their substance use, mental health, treatment involvement and functioning. the goal of this study is to better understand how people with opioid use disorder recover over time to improve intervention for this group.

this is a longitudinal follow-up study that will collect yearly outcomes data on adults with opioid use disorder (oud) who participated one of two prior clinical trials in the nida clinical trials network. this longitudinal, observational study will entail annual phone and online assessments of domains of interest (e.g., substance use, treatment engagement) as well as monthly assessments that are distributed via text messaging and email to be completed electronically by the participant. no participant randomization will occur for this study, and study data will be considered observational in nature. we aim to characterize the long-term course of oud and to evaluate the long-term course and recovery of oud.

Eligibility criteria:
inclusion criteria: 1. be an enrolled participant in one of two applicable clinical trials and be no longer than 24 months after the final expected assessment for that trial. 2. be willing and able to provide locator information for survey distribution (mobile number and/or email address). 3. be willing to allow the linkage of prior clinical trial study data to the current study record. exclusion criteria: 1. unable to understand or communicate to complete consent or study assessments. 2. are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities. 3. other factors that would cause harm or increased risk to the participant or close contacts or preclude the participant's full adherence with or completion of the study.
glulisine + lantus in type i patients

Conditions: Diabetes Mellitus, Type 1

Summary: to evaluate the efficacy (in terms of change hba1c from baseline to endpoint) and safety (in terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (hmr 1964) in subjects with type i diabetes mellitus


Eligibility criteria:
inclusion criteria: * type i diabetes mellitus (onset of diabetes under the age of 40), * an hba1c range of \>6.5 - \<11%, * and on multiple injection regimen (more than 1 year of continuous insulin treatment), * body mass index \<35. exclusion criteria: * active proliferative diabetic retinopathy, * diabetes other than type i diabetes mellitus, * pancreatectomised subjects, * subjects who have undergone pancreas and or islet cell transplants, * requiring treatment with not permited drugs during the study, * previous treatment (in the period not less than 1 month before the beginning of the trial) with insulin glargine, * hypersensitivity to insulin, * major systemic diseases, * impaired hepatic or renal function the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.